Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin in Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renal transplant recipient transplanted more than 1 year ago~* Stable renal function (\<20% deviation in serum creatinine within last 2 months)~* Stable immunosuppressive therapy ≥3 months before inclusion~* Diagnosed with PTDM:~(fasting plasma glucose ≥7.0 mmol/l and/or 2-hour plasma glucose ≥11.1 mmol/l following an oral glucose tolerance test)~-Signed informed consent and expected cooperation of the patients~Exclusion Criteria:~* Estimated GFR \<30 ml/min/1.73 m2~* Pregnant or nursing mothers~* Hypersensitivity to the active substance (IMP) or to any of the excipients~* Any reason why, in the opinion of the investigator, the patient should not participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: ACTIVE_COMPARATOR): 10 mg once daily for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 1 capsule once daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).